TORONTO, June 30, 2017 /PRNewswire/ – GeneNews Limited (TSX:GEN) (“GeneNews” or the “Company”) today announced that all of the nominee directors listed in the Company’s management information circular dated May 29, 2017, were elected as directors of the Company. The vote was conducted at the Company’s annual and special meeting of shareholders held on June 29, 2017. The results of the vote are set out below:
|
Nominee |
Votes For |
Votes |
Percentage |
Percentage |
|
James Howard-Tripp |
17,175,396 |
439,000 |
97.51 |
2.49 |
|
Rory Riggs |
17,190,396 |
424,000 |
97.59 |
2.41 |
|
Garth MacRae |
17,195,396 |
419,000 |
97.62 |
2.38 |
|
Harry Glorikian |
17,189,730 |
424,666 |
97.59 |
2.41 |
|
Leslie Auld |
17,169,730 |
444.666 |
97.48 |
2.52 |
|
Thomas D. Stewart, Jr. |
17,474,930 |
139,466 |
99.21 |
0.79 |
About GeneNews
GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. GeneNews’ mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health outcomes through the early diagnosis of disease. GeneNews’ Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient populations. Currently, Innovative Diagnostic Laboratory (“IDL”) offers risk assessment blood tests for four prevalent cancer types – colon, lung, prostate and breast. GeneNews’ common shares trade on the Toronto Stock Exchange under the symbol ‘GEN’. More information on GeneNews and IDL can be found at www.GeneNews.com and www.myinnovativelab.com, respectively.
SOURCE GeneNews Limited
Related Links
More news releases in similar topics
